Oppenheimer Initiated Crispr Therapeutics AG (CRSP)’s Coverage; Shorts at Celgene (CELG) Lowered By 12.19%

December 7, 2017 - By Vivian Park

Among 3 analysts covering CRISPR Therapeutics AG – Common Shares (CRSP), 1 have Buy rating, 0 Sell and 2 Hold. Therefore 33% are positive. CRISPR Therapeutics AG – Common Shares has $16 highest and $16.0 lowest target. $16’s average target is -15.35% below currents $18.9016 stock price. CRISPR Therapeutics AG – Common Shares had 6 analyst reports since July 14, 2017 according to SRatingsIntel. As per Monday, July 17, the company rating was initiated by Oppenheimer. On Friday, August 11 the stock rating was maintained by Chardan Capital Markets with “Buy”. The firm has “Hold” rating by Oppenheimer given on Tuesday, August 22. The company was maintained on Thursday, August 10 by Oppenheimer. The stock of CRISPR Therapeutics AG (NASDAQ:CRSP) earned “Hold” rating by SunTrust on Thursday, November 9.

Celgene Corporation (NASDAQ:CELG) had a decrease of 12.19% in short interest. CELG’s SI was 8.92M shares in December as released by FINRA. Its down 12.19% from 10.16 million shares previously. With 15.96 million avg volume, 1 days are for Celgene Corporation (NASDAQ:CELG)’s short sellers to cover CELG’s short positions. The SI to Celgene Corporation’s float is 1.15%. The stock increased 0.07% or $0.07 during the last trading session, reaching $102.24. About 239,977 shares traded. Celgene Corporation (NASDAQ:CELG) has risen 17.00% since December 7, 2016 and is uptrending. It has outperformed by 0.30% the S&P500.

Among 31 analysts covering Celgene Corporation (NASDAQ:CELG), 20 have Buy rating, 2 Sell and 9 Hold. Therefore 65% are positive. Celgene Corporation had 111 analyst reports since July 21, 2015 according to SRatingsIntel. Wells Fargo maintained Celgene Corporation (NASDAQ:CELG) on Friday, December 4 with “Outperform” rating. The company was maintained on Monday, October 30 by Credit Suisse. Canaccord Genuity maintained it with “Buy” rating and $156.0 target in Monday, October 16 report. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Thursday, October 19 by RBC Capital Markets. The firm has “Buy” rating given on Wednesday, October 4 by RBC Capital Markets. On Friday, October 20 the stock rating was downgraded by Robert W. Baird to “Neutral”. The stock of Celgene Corporation (NASDAQ:CELG) earned “Buy” rating by Canaccord Genuity on Friday, October 27. The stock of Celgene Corporation (NASDAQ:CELG) has “Buy” rating given on Sunday, August 13 by Jefferies. The rating was maintained by UBS with “Buy” on Friday, October 27. Barclays Capital maintained Celgene Corporation (NASDAQ:CELG) rating on Friday, October 20. Barclays Capital has “Equal-Weight” rating and $135 target.

Investors sentiment increased to 1.34 in Q2 2017. Its up 0.21, from 1.13 in 2017Q1. It is positive, as 60 investors sold Celgene Corporation shares while 390 reduced holdings. 110 funds opened positions while 494 raised stakes. 602.51 million shares or 1.81% more from 591.78 million shares in 2017Q1 were reported. Covington Capital Mngmt has invested 0.96% in Celgene Corporation (NASDAQ:CELG). Selkirk Mngmt Limited Liability Corp has invested 18.27% in Celgene Corporation (NASDAQ:CELG). Ing Groep Nv reported 0.44% stake. Calamos Wealth Management Lc has invested 0.34% in Celgene Corporation (NASDAQ:CELG). Franklin Street Advsr Inc Nc invested in 0.23% or 10,475 shares. Massmutual Tru Fsb Adv holds 0% or 21,401 shares. Natixis stated it has 3,692 shares. Meristem Llp reported 0.14% in Celgene Corporation (NASDAQ:CELG). Moreover, Price T Rowe Associate Inc Md has 0.29% invested in Celgene Corporation (NASDAQ:CELG) for 12.37 million shares. Iberiabank Corp stated it has 0.42% in Celgene Corporation (NASDAQ:CELG). Arizona State Retirement System reported 0.35% of its portfolio in Celgene Corporation (NASDAQ:CELG). Brandywine Inv Ltd Liability Co has 0.32% invested in Celgene Corporation (NASDAQ:CELG). The Texas-based Chilton Cap Mngmt Ltd Company has invested 1.14% in Celgene Corporation (NASDAQ:CELG). Martin Invest Management Lc holds 113,304 shares. Retail Bank Of Hawaii has 16,627 shares for 0.19% of their portfolio.

Since June 15, 2017, it had 0 buys, and 3 insider sales for $2.36 million activity. Friedman Michael A had sold 5,000 shares worth $625,000. $1.16M worth of Celgene Corporation (NASDAQ:CELG) was sold by CASEY MICHAEL D. VESSEY RUPERT had sold 4,785 shares worth $575,038 on Thursday, June 15.

Celgene Corporation discovers, develops, and commercializes therapies to treat cancer and inflammatory diseases worldwide. The company has market cap of $80.50 billion. It offers REVLIMID, an oral immunomodulatory drug for multiple myeloma, myelodysplastic syndromes , and mantle cell lymphoma; POMALYST/IMNOVID to treat multiple myeloma; OTEZLA, a small-molecule inhibitor of phosphodiesterase 4 for psoriatic arthritis, psoriasis, and ankylosing spondylitis; and ABRAXANE, a solvent-free chemotherapy product to treat breast, non-small cell lung, pancreatic, and gastric cancers. It has a 31.66 P/E ratio. The companyÂ’s products also include VIDAZA, a pyrimidine nucleoside analog for intermediate-2 and high-risk MDS, chronic myelomonocytic leukemia, and acute myeloid leukemia (AML); THALOMID to treat patients with multiple myeloma and erythema nodosum leprosum; and RITALIN and FOCALIN XR products.

Analysts await CRISPR Therapeutics AG (NASDAQ:CRSP) to report earnings on March, 9. They expect $-0.74 EPS, down 85.00% or $0.34 from last year’s $-0.4 per share. After $-0.62 actual EPS reported by CRISPR Therapeutics AG for the previous quarter, Wall Street now forecasts 19.35% negative EPS growth.

The stock increased 2.01% or $0.3716 during the last trading session, reaching $18.9016. About 18,448 shares traded. CRISPR Therapeutics AG (CRSP) has 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter:

Twitter Auto Publish Powered By : XYZScripts.com